Nina Krause

Nina Krause

Auto-generated profile, based on publicly available information

Nina Krause

Department of Veterinary Medicine, Lab of Viral Zoonotics, University of Cambridge, Cambridge, UK

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 October 2025 in Journal of General Virology
Verified
Journal Article
Open access
MPMartina Pfranger
Martina Pfranger
NKNina Krause
Nina Krause
BABenedikt Asbach
Benedikt Asbach
JMJohannes Meier
Johannes Meier
GCGeorge William Carnell
George William Carnell
RWRalf Wagner
Ralf Wagner
A multivalent vaccine targeting high-consequence infectious diseases in Sub-Saharan Africa (SSA), which are linked to high mortality, morbidity and overlapping clinical manifestations, would significantly improve health security and economic stability in this region. Trivalent vector vaccines were devised to deliver digitally optimized versions of Orthoebolavirus, Orthomarburgvirus glycoproteins (GPs) and a Lassa mammarenavirus (LASV) nucleoprotein (NP) by a single Modified Vaccinia Ankara (MVA) known to protect against mpox virus (MPXV) along with a matched DNA vaccine. Three immunizations in mice and Hartley guinea pigs with MVA only or a DNA prime followed by two MVA administrations induced comparable levels of binding antibodies and LASV-specific T-cells, respectively. While DNA priming mitigated MVA-specific antibody responses, GP- and NP-specific antibodies developed already after a single MVA vaccination. Although a post-outbreak Ebola virus vaccine is available, outbreaks by other filoviruses, annual LASV epidemics and increased incidence of MPXV infections support the rationale for an MVA-based trivalent haemorrhagic fever vaccine for endemic and high-risk human populations in SSA.

11 April 2025
Verified
Journal Article
Open access
PDF file
IGIraa Gupta
Iraa Gupta
NKNina Krause
Nina Krause
Tuberculosis (TB), caused by Mycobacterium tuberculosis (M. tuberculosis), remains a leading cause of global mortality. This review explores M. tuberculosis’s immune evasion mechanisms, including its inhibition of phagosome-lysosome fusion, resistance to reactive oxygen and nitrogen species, and interference with host signaling pathways. M. tuberculosis secretes proteins such as PknF, which inhibits NLRP3 inflammasome activation, and employs lipid-mediated defenses against host immune responses. The bacterium’s persistence in granulomas complicates eradication and enables it to develop antibiotic resistance. Existing treatments, such as first-line antibiotics, face limitations due to this rising drug resistance. Research into the role of proteins such as ESAT-6, DRAM1, and BNIP3 in M. tuberculosis pathogenesis may lead to new drug targets. Additionally, host-directed therapies, including Vps18-mediated lysosomal repair, have shown potential in improving TB treatment outcomes. Novel therapies, including small-molecule inhibitors targeting bacterial kinases, host-directed therapies, and phage therapy, offer promising alternatives. Traditional healing methods, such as the spread of ‘good nigudah’ often reveals scientific phenomena at work, such as the presence of immunogenic extracellular vesicles (EVs) abundant in M tuberculosis antigen in the breath aerosols of tuberculosis smear-negative, hymn-chanting congregation of the faithful. Dismissing such traditional practices that provide herd immunity, as hearsay, may hence prove detrimental. Understanding M. tuberculosis’s pathogenesis and immune evasion is crucial for developing effective treatments and vaccines against this persistent pathogen.